This segment focuses on the research, development, and clinical trials of Sollpura, a non-porcine pancreatic enzyme replacement therapy (PERT) for patients with exocrine pancreatic insufficiency (EPI). Research and development activities include Phase III clinical trials to evaluate the efficacy and safety of Sollpura in treating EPI. The technology involves the formulation and delivery of pancreatic enzymes to aid in digestion. The therapeutic area is EPI, a condition where the pancreas does not produce enough enzymes to digest food properly. The patient impact is improved nutrient absorption and reduced gastrointestinal symptoms. Market positioning involves competing with existing PERT products while offering a non-porcine alternative. Future opportunities include expanding the use of Sollpura and potentially gaining regulatory approvals. Clinical aspects involve rigorous testing and adherence to regulatory guidelines. Partnerships with Eli Lilly and Company have been established for the acquisition of Sollpura.

This segment is dedicated to the development of Blisibimod, a drug in Phase II clinical trials, for the treatment of B-cell mediated autoimmune diseases, including IgA nephropathy. Research and development activities include clinical trials to assess the safety and efficacy of Blisibimod. The technology involves targeting and modulating B-cell activity to reduce inflammation and disease progression. The therapeutic areas include IgA nephropathy and other B-cell mediated autoimmune diseases. The patient impact is the potential to slow or halt disease progression and improve quality of life. Market positioning involves addressing unmet medical needs in autoimmune diseases. Future opportunities include expanding the clinical trials and seeking regulatory approvals. Clinical aspects involve rigorous testing and adherence to regulatory guidelines. The company has a partnership with Zenyaku Kogyo Co., Ltd. for the development of Blisibimod.